DiaMedica Therapeutics Inc. Q1 FY2025 earnings call

Rick Pauls started by updating on clinical development programs. For the preeclampsia program, Part 1a of Phase 2 investigator-sponsored trial is close to identifying a target dose for Part 1b, with preliminary top-line results expected between second half of June and first half of July, dependent on lab schedules including placental transfer analysis. They'll sponsor a preeclampsia KOL call on May 28. For the stroke program, enrollment is between 20th-25th percentile for interim analysis, with interim analysis on first 200 participants in first half of 2026. They engaged a stroke neurologist to support site engagement. Scott Kellen discussed financials: as of March 31, 2025, cash and investments were 37.3 million, current liabilities 4.7 million, working capital 32.8 million. R&D expenses increased to 5.7 million, G&A expenses to 2.5 million, net other income 443,000.

Preeclampsia: Expect to release preliminary top-line results between second half of June and first half of July; anticipate Part 1b start in Q3. Stroke: Interim analysis on first 200 participants in first half of 2026.

Q: Clarify laboratory test results variable between June and July, specifically placental transfer test.

A: Yes, the main item is placental transfer assay being finalized and needing time to run.

Q: Triggers for Part 1b, Part 2, 3 in preeclampsia.

A: Fetal growth restriction based on intrauterine artery dilation; more on Part 2 when results are released.

Q: Read-through between preeclampsia data and AIS development.

A: Positive effect in preeclampsia confirms protein activity, references to crude forms in Asia used for stroke.

Q: Enrollment update for stroke, centers, geographic footprint.

A: Current in mid-30s, high enrolling sites, some in Georgia, enrollment uptick.

Q: Part 2 and 3 location for preeclampsia.

A: Part 2 and 3 in same protocol, no need for regulatory clearance, plan to expand to US and global later.